Skip to main content
. Author manuscript; available in PMC: 2011 Aug 1.
Published in final edited form as: Exp Dermatol. 2008 Mar 13;17(9):752–760. doi: 10.1111/j.1600-0625.2008.00716.x

Figure 4.

Figure 4

Tetracycline (TCN) dose-dependently inhibits tumor necrosis factor (TNF)α-induced CXCL8 and CXCL1 production by human microvascular endothelial cell line-1 (HMEC-1). (a) CXCL8: HMEC-1 cells were cultured in the presence of TCN for 30 min followed by addition of TNFα to 0.02 μg/ml. Supernatants were collected 24 h later and analysed for CXCL8 content. Note that TNFα enhances CXCL8 release. Error bars indicate ± SD (P = 0.027 and P = 0.015, respectively, for TCN of 40 and 80 μg/ml compared with 0 μg/ml for the no ATPγS groups). (b) CXCL1: HMEC-1 cells were cultured in the presence of TCN for 30 min followed by addition of TNFα to 0.02 μg/ml. The supernatants were collected 24 h later and analysed for CXCL1 content. Note that TNFα enhances CXCL1 release. Error bars indicate ± SD (P = 0.029, <0.001, <0.001 and <0.001, respectively, for TCN 10, 20, 40 and 80 μg/ml compared with 0 μg/ml for the no TNFα group).